ADCT - Adc Therapeutics SA

4.8
0.570   11.875%

Share volume: 1,561,241
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$4.23
0.57
0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 43%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
16.79%
1 Month
22.45%
3 Months
14.83%
6 Months
44.14%
1 Year
179.07%
2 Year
7.87%
Key data
Stock price
$4.80
P/E Ratio 
0.00
DAY RANGE
$4.20 - $4.95
EPS 
-$1.34
52 WEEK RANGE
$1.05 - $4.95
52 WEEK CHANGE
$159.46
MARKET CAP 
449.998 M
YIELD 
N/A
SHARES OUTSTANDING 
123.877 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
1.73
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,127,307
AVERAGE 30 VOLUME 
$889,160
Company detail
CEO: Ameet Mallik
Region: US
Website: adctherapeutics.com
Employees: 310
IPO year: 2020
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial.

Recent news